acalabrutinib:新一代布鲁顿酪氨酸激酶抑制剂

Acalabrutinib as a latest generation Bruton tyrosine kinase inhibitor

acalabrutinib是由阿斯利康制药公司开发的新一代布鲁顿酪氨酸激酶(BTK)抑制剂,于2017年10月31日经美国食品和药物管理局批准上市,用于治疗套细胞淋巴瘤。最近的研究表明,acalabrutinib对慢性淋巴细胞白血病也有良好的疗效。acalabrutinib比依鲁替尼具有更好的选择性和安全性,最常见的不良反应为头痛和腹泻。

Acalabrutinib which was developed by Astra Zeneca, is a latest generation Bruton tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration on October 31, 2017 for the treatment of mantle cell lymphoma. Recent clinical trials have showed that some patients with chronic lymphocytic leukaemia also respond positively to acalabrutinib. Acalabrutinib is clinically demonstrated to be more potent and selective than ibrutinib, and its common adverse reactions include headache and diarrhea.